Cargando…

The Effects of 2′-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials

A thorough analysis of clinical trial data in the Ionis integrated safety database (ISDB) was performed to determine if there is a class effect on platelet numbers and function in subjects treated with 2′-O-methoxyethyl (2′MOE)-modified antisense oligonucleotides (ASOs). The Ionis ISDB includes over...

Descripción completa

Detalles Bibliográficos
Autores principales:	Crooke, Stanley T., Baker, Brenda F., Witztum, Joseph L., Kwoh, T. Jesse, Pham, Nguyen C., Salgado, Nelson, McEvoy, Bradley W., Cheng, Wei, Hughes, Steven G., Bhanot, Sanjay, Geary, Richard S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467133/ https://www.ncbi.nlm.nih.gov/pubmed/28145801 http://dx.doi.org/10.1089/nat.2016.0650

Ejemplares similares

The Effects of 2′-O-Methoxyethyl Oligonucleotides on Renal Function in Humans
por: Crooke, Stanley T., et al.
Publicado: (2018)

Improvements in the Tolerability Profile of 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides in Parallel with Advances in Design, Screening, and Other Methods
por: Partridge, Wesley, et al.
Publicado: (2021)

Integrated Safety Assessment of 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers
por: Crooke, Stanley T, et al.
Publicado: (2016)

Integrated Assessment of Phase 2 Data on GalNAc(3)-Conjugated 2′-O-Methoxyethyl-Modified Antisense Oligonucleotides
por: Baker, Brenda F., et al.
Publicado: (2023)

Integrated Assessment of the Clinical Performance of GalNAc(3)-Conjugated 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience
por: Crooke, Stanley T., et al.
Publicado: (2019)

Clinical and Preclinical Pharmacokinetics and Pharmacodynamics of Mipomersen (Kynamro(®)): A Second-Generation Antisense Oligonucleotide Inhibitor of Apolipoprotein B
por: Geary, Richard S., et al.
Publicado: (2015)

Molecular Mechanisms of Antisense Oligonucleotides
por: Crooke, Stanley T.
Publicado: (2017)

Sequence-specific 2'-O-methoxyethyl antisense oligonucleotides activate human platelets through glycoprotein VI, triggering formation of platelet-leukocyte aggregates
por: Slingsby, Martina H. Lundberg, et al.
Publicado: (2021)

Effective Exon Skipping and Dystrophin Restoration by 2′-O-Methoxyethyl Antisense Oligonucleotide in Dystrophin-Deficient Mice
por: Yang, Lu, et al.
Publicado: (2013)

Predictive Dose-Based Estimation of Systemic Exposure Multiples in Mouse and Monkey Relative to Human for Antisense Oligonucleotides With 2′-O-(2-Methoxyethyl) Modifications
por: Yu, Rosie Z, et al.
Publicado: (2015)

Lack of QT Prolongation for 2′-O-Methoxyethyl-Modified Antisense Oligonucleotides Based on Retrospective Exposure/Response Analysis of Ten Phase 1 Dose-Escalation Placebo-Controlled Studies in Healthy Subjects
por: Yu, Rosie Z., et al.
Publicado: (2017)

Treatment with Volanesorsen, a 2′-O-Methoxyethyl-Modified Antisense Oligonucleotide Targeting APOC3 mRNA, Does Not Affect the QTc Interval in Healthy Volunteers
por: Watts, Lynnetta M., et al.
Publicado: (2020)

Defining the Factors That Contribute to On-Target Specificity of Antisense Oligonucleotides
por: Lima, Walt F., et al.
Publicado: (2014)

Antisense technology: A review
por: Crooke, Stanley T., et al.
Publicado: (2021)

Annexin A2 facilitates endocytic trafficking of antisense oligonucleotides
por: Wang, Shiyu, et al.
Publicado: (2016)

Efficient Synthesis of 2’‐O‐Methoxyethyl Oligonucleotide‐Cationic Peptide Conjugates
por: Halloy, François, et al.
Publicado: (2021)

Membrane Destabilization Induced by Lipid Species Increases Activity of Phosphorothioate-Antisense Oligonucleotides
por: Wang, Shiyu, et al.
Publicado: (2018)

Nucleic acid binding proteins affect the subcellular distribution of phosphorothioate antisense oligonucleotides
por: Bailey, Jeffrey K., et al.
Publicado: (2017)

The rates of the major steps in the molecular mechanism of RNase H1-dependent antisense oligonucleotide induced degradation of RNA
por: Vickers, Timothy A., et al.
Publicado: (2015)

COPII vesicles can affect the activity of antisense oligonucleotides by facilitating the release of oligonucleotides from endocytic pathways
por: Liang, Xue-hai, et al.
Publicado: (2018)

Effects of an Antisense Oligonucleotide Inhibitor of C‐Reactive Protein Synthesis on the Endotoxin Challenge Response in Healthy Human Male Volunteers
por: Noveck, Robert, et al.
Publicado: (2014)

Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides
por: Anderson, Brooke A, et al.
Publicado: (2021)

mRNA levels can be reduced by antisense oligonucleotides via no-go decay pathway
por: Liang, Xue-hai, et al.
Publicado: (2019)

RNA cleavage products generated by antisense oligonucleotides and siRNAs are processed by the RNA surveillance machinery
por: Lima, Walt F., et al.
Publicado: (2016)

Translation can affect the antisense activity of RNase H1-dependent oligonucleotides targeting mRNAs
por: Liang, Xue-Hai, et al.
Publicado: (2018)

Targeting of Repeated Sequences Unique to a Gene Results in Significant Increases in Antisense Oligonucleotide Potency
por: Vickers, Timothy A., et al.
Publicado: (2014)

Antisense Oligonucleotides Capable of Promoting Specific Target mRNA Reduction via Competing RNase H1-Dependent and Independent Mechanisms
por: Vickers, Timothy A., et al.
Publicado: (2014)

Intra-endosomal trafficking mediated by lysobisphosphatidic acid contributes to intracellular release of phosphorothioate-modified antisense oligonucleotides
por: Wang, Shiyu, et al.
Publicado: (2017)

RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus
por: Liang, Xue-Hai, et al.
Publicado: (2017)

Antisense oligonucleotides targeting translation inhibitory elements in 5′ UTRs can selectively increase protein levels
por: Liang, Xue-hai, et al.
Publicado: (2017)

Antisense oligonucleotides targeting angiotensinogen: insights from animal studies
por: Wu, Chia-Hua, et al.
Publicado: (2019)

Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2′-modifications and enhances antisense activity
por: Liang, Xue-Hai, et al.
Publicado: (2016)

Cellular uptake mediated by epidermal growth factor receptor facilitates the intracellular activity of phosphorothioate-modified antisense oligonucleotides
por: Wang, Shiyu, et al.
Publicado: (2018)

Golgi-endosome transport mediated by M6PR facilitates release of antisense oligonucleotides from endosomes
por: Liang, Xue-hai, et al.
Publicado: (2020)

Peptide Conjugates of a 2′-O-Methoxyethyl Phosphorothioate Splice-Switching Oligonucleotide Show Increased Entrapment in Endosomes
por: Hill, Alyssa C., et al.
Publicado: (2023)

Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data
por: Viney, Nicholas J., et al.
Publicado: (2020)

Enhancement of SMN2 Exon 7 Inclusion by Antisense Oligonucleotides Targeting the Exon
por: Hua, Yimin, et al.
Publicado: (2007)

Antisense oligonucleotides in neurological disorders
por: Wurster, Claudia D., et al.
Publicado: (2018)

Antisense oligonucleotides: A primer
por: Scoles, Daniel R., et al.
Publicado: (2019)

Antisense Oligonucleotides and RNA Interference
por: Kher, Gitanjali, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_rkv5qtocaf55le1fj2rnrkia54